SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) — AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its executive leadership team, are scheduled to participate in multiple upcoming investor conferences:
Guggenheim Emerging Outlook: Biotech Summit 2026, New York, NY
Format – Fireside chat and 1×1 investor meetingsDate and Time – Wednesday, Feb. 11, 2026 at 3:00pm ET
Piper Sandler Virtual Novel Targets in Immunology Symposium, Virtual
Format – Fireside chatDate and Time – Thursday, Feb. 12, 2026 at 12:30pm ET
TD Cowen 46th Annual Health Care Conference, Boston, MA
Format – Fireside chat and 1×1 investor meetingsDate and Time – Wednesday, Mar. 4, 2026 at 11:50am ET
Barclays 28th Annual Global Healthcare Conference, Miami, FL
Format – Fireside chat and 1×1 investor meetingsDate and Time – Tuesday, Mar. 10, 2026 at 8:30am ET
UBS Biotech Summit Miami: Catalyst for Change, Miami, FL
Format -1×1 investor meetingsDate and Time – Tuesday, Mar. 10, 2026
Leerink Global Healthcare Conference, Miami FL
Format – Fireside chat and 1×1 investor meetingsDate and Time – Wednesday, Mar. 11, 2026 at 2:20pm ET
Live webcasts of the fireside chats will be available on the investor section of the Anaptys website at https://ir.anaptysbio.com/presentations-and-events. Replays of the webcasts will be available for at least 30 days following the events.
About Anaptys
Anaptys is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. The company’s pipeline includes rosnilimab, a pathogenic T cell depleter, which has completed a Phase 2b trial for rheumatoid arthritis; ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease and eosinophilic esophagitis; and ANB101, a BDCA2 modulator, in a Phase 1a trial. Anaptys has also discovered and out-licensed in financial collaborations multiple therapeutic antibodies, including a PD-1 antagonist (Jemperli (dostarlimab-gxly)) to GSK and an IL-36R antagonist (imsidolimab) to Vanda Pharmaceuticals. To learn more, visit http://www.AnaptysBio.com or follow us on LinkedIn.
Anaptys recently announced the intent to separate its biopharma operations from its substantial royalty assets by year-end 2026, enabling investors to align their investment philosophies and portfolio allocation with the strategic opportunities and financial objectives of each company. Learn more here.
Contact:
Nick Montemarano
Executive Director, Investor Relations
858.732.0178
[email protected]
